Analyst Pin-board Pharmaceutical – Bright outlook for 2H2022
- In the hospital channel, domestic drugs are a lower proportion than foreign drugs, and the percentage of winning bids is only 33% less than 67% of foreign drugs. The brand-name drugs are 100% foreign, accounting for the majority in groups 1, 5 and the same proportion as domestic drugs in group 2. Domestic drug manufacturers focus on competing in groups 2, 3, and 4.
- Market-wide pharmaceutical sales improved in 1H2022 after the Omicron variant. From the low base of 2H/2021, we expect domestic drug manufacturing businesses to grow strongly in the short term.
- The sales channel is expanding through the race for market share and the trend of aging in Vietnam to create favorable conditions for the pharmaceutical industry in the medium and long term.
Viet Dragon Securities belongs to top 20 biggest securities companies in terms of chartered capital in Vietnam. With a qualified, dedicated and professional team, a widespread network, advanced technology, diversified products and services, and good relationship with local and foreign institutions, we provide a wide range of services and products to our clients both individuals and institutions, both local and foreign. We commit to provide our clients with promising investment opportunities and a comprehensive and professional financial investment services.
RongViet Research reports are diversified and abundant, along with in-depth analysis and performed by experienced, highly-qualified and knowledgeable teams. With the objectives of transparency, accurate and timely manner, RongViet believes that our products would always be important sources of information for customers/investors’ investment decisions.”
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.